How to buy Cortexyme stock - 14 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cortexyme stock

Own Cortexyme stock in just a few minutes.

Cortexyme, Inc is a biotechnology business based in the US. Cortexyme shares (CRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Cortexyme employs 37 staff and has a market cap (total outstanding shares value) of USD$993 million.

How to buy shares in Cortexyme

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Cortexyme. Find the stock by name or ticker symbol: CRTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cortexyme reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Cortexyme, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Cortexyme. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Cortexyme share price

Use our graph to track the performance of CRTX stocks over time.

Cortexyme shares at a glance

Information last updated 2021-04-08.
52-week rangeUSD$26.6612 - USD$58.99
50-day moving average USD$35.4889
200-day moving average USD$40.6492
Wall St. target priceUSD$66.63
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.169

Buy Cortexyme shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cortexyme stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cortexyme financials

Gross profit TTM USD$0
Return on assets TTM -31.42%
Return on equity TTM -53.42%
Profit margin 0%
Book value $5.831
Market capitalisation USD$993 million

TTM: trailing 12 months

Shorting Cortexyme shares

There are currently 3.2 million Cortexyme shares held short by investors – that's known as Cortexyme's "short interest". This figure is 1.2% down from 3.3 million last month.

There are a few different ways that this level of interest in shorting Cortexyme shares can be evaluated.

Cortexyme's "short interest ratio" (SIR)

Cortexyme's "short interest ratio" (SIR) is the quantity of Cortexyme shares currently shorted divided by the average quantity of Cortexyme shares traded daily (recently around 395937.46928747). Cortexyme's SIR currently stands at 8.14. In other words for every 100,000 Cortexyme shares traded daily on the market, roughly 8140 shares are currently held short.

However Cortexyme's short interest can also be evaluated against the total number of Cortexyme shares, or, against the total number of tradable Cortexyme shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cortexyme's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Cortexyme shares in existence, roughly 110 shares are currently held short) or 0.2078% of the tradable shares (for every 100,000 tradable Cortexyme shares, roughly 208 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Cortexyme.

Find out more about how you can short Cortexyme stock.

Cortexyme share dividends

We're not expecting Cortexyme to pay a dividend over the next 12 months.

Cortexyme overview

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site